Form 4: MAIA Biotechnology Director Louie Ngar Yee Reports Stock Option Grant

Director Louie Ngar Yee reports acquisition of stock options in MAIA Biotechnology, Inc.

Summary

• On October 1, 2024, Louie Ngar Yee, a director of MAIA Biotechnology, Inc., filed a Form 4.
• The form reports the grant of stock options to purchase 10,848 shares of common stock.
• These options were granted on September 30, 2024, under the company's 2021 Equity Incentive Plan.
• The exercise price of the options is $2.81.
• The options vest immediately and are exercisable from the grant date, expiring on September 30, 2034.
• Following the transaction, Louie Ngar Yee directly owns 10,848 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a standard stock option grant to a director, which is a common practice.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• Immediate vesting provides an incentive for continued service and performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize equity incentive plans to attract and retain talent.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• It incentivizes the director to work towards increasing shareholder value.

Key Dates